Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Price Crosses Above Two Hundred Day Moving Average of $21.94

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $21.94 and traded as high as $25.60. Global X Genomics & Biotechnology ETF shares last traded at $25.48, with a volume of 136,920 shares changing hands.

The firm has a 50 day moving average of $25.14 and a 200 day moving average of $22.00.

The business also recently announced a Semi-Annual dividend, which was paid on Friday, January 8th. Shareholders of record on Thursday, December 31st were given a dividend of $0.032 per share. The ex-dividend date of this dividend was Wednesday, December 30th.

An institutional investor recently bought a new position in Global X Genomics & Biotechnology ETF stock. Jane Street Group LLC bought a new position in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 34,641 shares of the company’s stock, valued at approximately $623,000. Jane Street Group LLC owned approximately 0.95% of Global X Genomics & Biotechnology ETF at the end of the most recent reporting period.

About Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.

Further Reading: How are the companies in the S&P 500 selected?

Receive News & Ratings for Global X Genomics & Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global X Genomics & Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.